6505--Montelukast Chewable Tablets

Amendment / Modification

This amendment extends the closing date for Solicitation 36E79726R0012.

• The hour and date for receipt of offers is extended.

• The original closing date of 03/03/2026 is extended to 03/10/2026 at 2:30 PM CT.

• All other terms and conditions of the original solicitation remain unchanged.

Solicitation

This solicitation seeks proposals for the supply of Montelukast Sodium (NA) tablets and capsules in various strengths and package sizes. The contract will establish National Contract prices for products distributed through the VA and DoD Pharmaceutical Prime Vendor (PPV) Programs. The objective is to ensure product availability and consistency nationwide and to obtain volume-based pricing.

• Products: Montelukast NA 4mg and 5mg tablets/chewables in 30-count, 90-count, and 1,000-count bottles. Specific quantities are estimated in Attachment C.

• Packaging: Unit-of-use bottles must meet specific size (min 120cc), safety cap, and labeling requirements (5.25" x 2" label). Bottles of 400 tablets/capsules or less require safety caps.

• Barcoding: All pharmaceutical products must include GS1-128 or HIBCC compliant bar code labeling at the unit-of-use package level.

• DSCSA Compliance: Adherence to Drug Supply Chain Security Act (DSCSA) requirements, including serialized DSCSA Transaction Information and Transaction Statements using GS1 EPCIS files.

• NDC: Offerors must provide a unique 11-digit National Drug Code (NDC) for each product offered.

• FDA Approval: Offered drugs must have verifiable FDA approval (NDA, ANDA, or BLA).

• cGMP: Manufacturing facilities must have acceptable FDA current Good Manufacturing Practices (cGMP) status.

• Cost Recovery Fee: A 0.5% Cost Recovery Fee must be included in all offered prices.

• Contract Type: Firm Fixed Price, Indefinite-Delivery Requirements contract.

• Ordering Period: Base year plus four one-year option periods.

• Distribution: Products will be distributed through Government Prime Vendor (PPV) contracts (McKesson, Cencora, Cardinal Health, DMS Pharmaceutical Group).

• Payment: Contractors will receive payments from PPVs, not directly from the Government.

• Submission: Proposals must be submitted via email in Microsoft Word or PDF format to Matthew.poulin@va.gov and Teresa.hussain@va.gov, including a scanned SF-1449. Faxed proposals are not acceptable.

• Pricing: Offerors must submit prices for all line items for the base year and all four option years. Prices should not exceed two decimal places.

• Evaluation: Award will be made to the responsible offeror with the lowest price technically acceptable offer. Technical acceptability includes meeting product descriptions, NDC requirements, FDA approval, and cGMP status. Past performance will also be evaluated.

• Deadline: Offerors must hold prices firm for 120 calendar days.

• Manufacturer Requirement: If the offeror is not the manufacturer, a Letter of Commitment from the manufacturer is required.

• Subcontracting Plan: Non-small business concerns must submit an approved subcontracting plan for contracts over $900,000.

• Offerors must maintain the same manufacturer (NDA/ANDA/BLA) for the duration of the contract unless a change is approved.

• Backorder procedures are detailed in Section 4 of the Scope of Contract.

• Covered drugs must meet Federal Ceiling Price (FCP) requirements.

Solicitation / RFP / RFQ

This is a pre-solicitation notice for an unrestricted procurement of Montelukast Sodium Chewable Tablets. The Department of Veterans Affairs (VA) National Acquisition Center intends to issue a Request for Proposal (RFP) for supply to the VA (including CMOPs and State Veterans Homes), Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC).

• Supply of Montelukast Sodium Chewable Tablets in specified package sizes (30, 90, 1000 tablets per bottle).

• Offerors must provide the exact name (as it appears on the label) and a unique NDC number for the drug.

• The successful offeror's label with its unique NDC will be the only label permitted on the product; labels cannot be affixed over existing ones.

• The contract will be awarded to a responsible offeror capable of providing an uninterrupted source of supply.

• The contract period will be one year with four pre-priced one-year option periods.

• Contract items will be distributed through the VA's and DoD's Pharmaceutical Prime Vendor Programs.

• The solicitation (RFP # 36E79726R0012) will be issued electronically in accordance with FAR Part 12 on or about February 17, 2026.

• The tentative closing date for proposals is March 3, 2026, 2:30 PM Central Time, Chicago, USA.

• All responsible sources may submit an offer.

• Interested offerors are advised to continuously check SAM.gov for amendments and updates.

• This is an unrestricted procurement.

• NAICS Code: 325412

• Product Service Code: 6505

• Estimated annual requirements for each item are provided in the document.

• The point of contact for this procurement is Matthew Poulin, Contract Specialist, at matthew.poulin@va.gov or 708-786-5186.